Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT | MicrobiomeTrials← Back to trialsNCT05983198
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-11-07Est. Completion: 2031-03-04
Enrollment target: 33 participants Locations- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Novartis Investigative Site, Darlinghurst, New South Wales, Australia
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Dijon, Cote D Or, France
- Novartis Investigative Site, Clermont-Ferrand, France
- Novartis Investigative Site, Lyon, France
- Novartis Investigative Site, Nantes, France
- Novartis Investigative Site, Saint-Herblain, France
- Novartis Investigative Site, Vandœuvre-lès-Nancy, France
Other microbiome trials you might be interested in
Prostate CancerRecurrent Prostate CancerMetastatic Prostate CancerProstate Cancer RecurrentProstate Cancer Metastatic
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression …
St Louis, United StatesEst. completion Nov 14, 2027
Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incide…
Hackensack, United StatesCompleted Oct 1, 2026
Recurrent Prostate CancerProstate Cancer
Background:
Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blo…
Bethesda, United StatesEst. completion Jan 30, 2029